Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition of notoginsen triterpenes and notoginsenoside

A technology of Panax notoginseng saponins and aescin, which is applied in the field of medicine to achieve the effect of improving drug efficacy, wide application prospects, and excellent drug efficacy

Inactive Publication Date: 2011-08-10
JIANGYIN TIANJIANG PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, using the interaction of Panax notoginseng saponins and sodium aescinate to combine prescriptions to treat cerebrovascular diseases has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0016] The mice were observed for one week in a breeding and observation room, the temperature of the observation room was 20±3°C, the relative humidity was 30-70%, and the light was 12 hours.

[0017] The test animals were randomly divided into 24 groups, and the test drugs and doses of each group are shown in Table 1 for details.

[0018] Test product: Panax notoginseng saponins, commercially available, content 65.4%;

[0019] Sodium aescinate: commercially available, content 99.2%;

[0020] Panax notoginseng saponins injection: 150mg.

[0021] Aescin sodium injection: 5mg.

[0022] Panax notoginseng total saponins and aescin sodium compatibility injection, self-made

[0023] Table 1: Grouping list of combined medication of Panax notoginseng and sodium aescinate

[0024] Experimental method: test animal is divided into 24 groups at random, according to the administration dosage listed in Table 1 respectively after intravenous injection, observe the death situation with...

experiment example 2

[0030] Test product: Panax notoginseng saponins, commercially available, content 65.4%;

[0031] Sodium aescinate: commercially available, content 99.2%;

[0032] Panax notoginseng saponins injection: 150mg

[0033] Aescin sodium injection: 5mg

[0034] Composition injection 1: self-made, Panax notoginseng saponins + sodium aescinate (100mg: 2mg);

[0035] Composition injection 2: self-made, Panax notoginseng saponins + sodium aescinate (100mg: 4mg);

[0036] Composition injection 3: self-made, Panax notoginseng saponins + sodium aescinate (100mg: 20mg);

[0037] Test method: Rats were randomly divided into 6 groups, 10 in each group, respectively control group, total notoginseng saponin injection group, sodium aescinate injection group, total notoginseng saponin and sodium aescinate composite composition Injection group (ratio of total notoginseng saponins to sodium aescinate 1:0.02, ratio of total notoginseng saponins to sodium aescinate 1:0.04, ratio of total notoginsen...

experiment example 3

[0044] Test product: Panax notoginseng saponins, commercially available, content 65.4%;

[0045] Sodium aescinate: commercially available, content 99.2%;

[0046] Panax notoginseng saponins injection: 150mg

[0047] Aescin sodium injection: 5mg

[0048] Composition injection 1: self-made, total saponins of Panax notoginseng: sodium aescinate = 100: 2mg;

[0049] Composition injection 2: self-made, total saponins of Panax notoginseng: sodium aescinate = 100: 4mg;

[0050] Composition injection 3: self-made, total saponins of notoginseng: sodium aescinate = 100: 20mg;

[0051] Test method: Take 30 mixed-breed dogs, weighing 11.0-13.0 kg, 5 dogs in each group, both male and female, and randomly divide them into 6 groups. The first group is 0.9% normal saline control group; Three different ratio groups of saponins and aescin sodium, the ratios are the ratio of total saponins of notoginseng and sodium aescinate 1:0.02, the ratio of total saponins of notoginseng and sodium aesci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition comprising notoginsen triterpenes and notoginsenoside or their pharmaceutically acceptable salts, preparation containing the pharmaceutical composition and its preparing process, the weight ratio of the two ingredients is 1:0.002-0.65. The composition can be prepared into any clinically or pharmaceutically acceptable dose forms, preferably injections. The composition has synergic action and good constancy.

Description

[technical field] [0001] The invention belongs to the technical field of medicine, and relates to a pharmaceutical composition containing total saponins of notoginseng and aescin or a pharmaceutically acceptable salt thereof, a preparation containing the pharmaceutical composition and a preparation method thereof. [Background technique] [0002] Cerebrovascular diseases are a group of diseases that occur in the blood vessels of the brain and cause brain tissue damage due to intracranial blood circulation disorders. Cerebrovascular disease is still a common disease all over the world, and it is one of the important causes of serious disability and death in human beings. Therefore, revealing the mechanism of the occurrence and development of cerebrovascular diseases, carrying out effective prevention, treatment and rehabilitation, and reducing disability and mortality have always been the direction that the medical profession is committed to. [0003] Panax notoginseng is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/258A61K31/704A61P9/00
Inventor 蔡军
Owner JIANGYIN TIANJIANG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com